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Sepsis has become a major health economic issue, with more patients dying in hospitals due to sepsis related complications
compared to breast and colorectal cancer together. Despite extensive research in order to improve outcome in sepsis over the last few
decades, results of large multicenter studies were by-and-large very disappointing. This fiasco can be explained by several factors,
but one of the most important reasons is the uncertain definition of sepsis resulting in very heterogeneous patient populations, and
the lack of understanding of pathophysiology, which is mainly based on the imbalance in the host-immune response. However, this
heroic research work has not been in vain. Putting the results of positive and negative studies into context, we can now approach
sepsis in a different concept, which may lead us to new perspectives in diagnostics and treatment. While decision making based
on conventional sepsis definitions can inevitably lead to false judgment due to the heterogeneity of patients, new concepts based
on currently gained knowledge in immunology may help to tailor assessment and treatment of these patients to their actual needs.
Summarizing where we stand at present and what the future may hold are the purpose of this review.
1. Introduction
One of the most challenging tasks in critical care medicine
is the treatment of serious infection related multiple organ
dysfunction, termed in general as sepsis, severe sepsis, and
septic shock. However, sepsis means a very heterogeneous
patient population, which varies in etiology and severity;
therefore, universally applicable diagnostic criteria and treat-
ment algorhythms are difficult to be defined.This heterogene-
ity proved to be one of the most difficult hurdles that most
prospective randomized trials could not concur; hence, they
failed to show either clear survival benefit or positive results
of single center studies that were later contradicted by large
multicenter trials [1]. Nevertheless, sepsis has become a very
important health economic issue all around the world.
Furthermore, treating sepsis is a multidisciplinary task.
Early recognition and commencing initial steps of resuscita-
tion are inevitable to give the best possible chance for survival,
which has to be started on the primary care level: outside the
hospital, in the emergency department or on thewards. In the
absence of adequate initial management, providing even the
highest level of intensive care would be in vain.
Although the results of prospective randomized clinical
trials may be disappointing as far as survival is concerned,
it is beyond doubt that we have learned a lot about the
pathophysiology of sepsis during performing these studies
over the last few decades. Understanding the immunological
background of the clinical picture is of utmost importance,
which enables the clinician to interpret results of diagnostic
tests and rationalize treatment modalities in the most appro-
priate way. To highlight a few of the current novelties in
sepsis pathophysiology and potential new perspectives is the
purpose of this review.
2. Sepsis Is Not a (Definitive) Disease
In medical school we were brought up in the world of
“definitive diagnoses.” This means that patients come in
with a certain complaint, the physician after taking medical
history, performing physical examination and diagnostic
tests, defines the diagnosis and treat the patient accordingly.
In the case of a well-defined disease more-or-less the same
or similar diagnostic tests and therapeutic interventions
are performed all around the world (such as stroke and
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myocardial infarction). This holds true for most diseases in
classical medicine and surgery. However, defining sepsis is
not that simple. The term we call “sepsis syndrome” was
conceived in a hotel room in Las Vegas in 1980, during the
protocol writing of one of the first prospective randomized
trials in sepsis, performed by a group of scientists led by
the late Roger Bone [2, 3]. Based on the inclusion criteria of
this study a statement paper was later published by the same
authors titled “Sepsis Syndrome: A Valid Clinical Entity”
[3]. However, these classical signs of the “sepsis syndrome,”
such as fever/hypothermia, leukocytosis/leukopenia, tachy-
cardia, and hypotension, meant a very large and nonspe-
cific/noninfectious cohort of patients. For this reason, a few
years later a consensus conference was brought together and
defined the so called “consensus criteria” of sepsis [4], which
has also been recently questioned and criticized by Vincent
et al. [5]. In the most current Surviving Sepsis Campaign
Guideline a more robust, more detailed definition has been
created, in order to “save” the previous concept of the Bone-
criteria [6].
These efforts clearly show that finding the appropriate
definition of sepsis has been a continuous challenge for more
than 30 years. The difficulty in defining sepsis originates
from its pathophysiology, to be discussed in Section 4. This
has been recognized by international societies and currently
an international Task Force has been working on a new,
pathophysiology based sepsis definition. Nevertheless, in
most specialties the disease itself is easily diagnosed by
a laboratory or radiological test. However, in the case of
sepsis it is different, which makes not just the diagnosis but
the interpretation of the results of clinical trials and also
epidemiological data very difficult.
3. Epidemiology
According to recent surveys we treat several folds more
critically ill patients on the intensive care units (ICU)
worldwide these days as compared to the figures from more
than 10 years ago [7]. There seems to be an increase in
the incidence of sepsis, with mortality rates of 20–50%,
and according to recent data from the United States, sepsis
is the single most expensive reason for hospitalization at
present [8, 9]. However, it is important to note that reported
mortality shows considerable variation across the globe. A
recent retrospective analysis fromAustralia andNewZealand
showed an increase in the number of critically ill and septic
patients over the last 12 years, with a mortality reduction
from more than 30% to less than 20% [7]. In the PROCESS
trial from the United States mortality was around 20% [10].
According to these data outcome has improved dramatically
over the years. However, results from Europe, both retro-
spective and prospective, indicate greater mortality of 45–
55%, which was also accompanied by a 2- to 3-fold longer
ICU and hospital stay [11, 12], as compared to that reported
by the two previously mentioned studies. This raises the
question ofwhether the care is better in those countrieswhich
reported lower mortality rate or is it the patient selection
that causes this difference? Although it is difficult to give a
definitive answer, referring to our previous chapter, due to
the difficulties in defining sepsis, severe sepsis, and septic
shock, one cannot exclude that this difference can be the
result of the uncertainties in patient selection, and, in those
countries reporting higher mortality rates, sicker patients
were included in the “septic shock” cohort.
Indeed, patients with the same diagnosis of “septic shock”
could have completely different severity and prognosis. The
same holds true for every potential “insult” in critical care,
such as trauma, sterile inflammation (acute pancreatitis),
ischemia-reperfusion injury, major surgery, burns, and infec-
tion. These conditions share the same feature in their patho-
physiology, namely, that it is not the insult per se, but the host’s
response, especially the immune response, which determines
severity and outcome (Figure 1).
4. Pathophysiology
4.1. From Localized Insult to “Cytokine Storm”. The immune
system is a “team effort” that involves many different players
interacting with each other as an orchestra. The immune
response to pathogens relies on both innate and adaptive
components.Thefirst line of defense against invaders consists
of physical barriers such as the skin [13, 14], the mucous
membranes of our gastrointestinal [15], and respiratory [16]
and genitourinary [17] tracts. The second line is the rapid
defense by the innate immune system (including complement
proteins, sentinel phagocyte cells, and natural killer cells),
which plays an activator and a controller role of the adaptive
immune system [18]. The innate system acts by broad recog-
nition of antigens, mainly by sensing pathogen-associated
molecular patterns (PAMP) of carbohydrates and fatty acids
located on the surfaces of common pathogens. By-and-large
when a local response spread systemically the activation of
several classes of pattern recognition receptors will generate
a “cytokine-chemokine storm” [19]. However, very similar
molecules are released due to cell injury after trauma, burns,
ischemia-reperfusion, pancreatitis, major surgery, and so
forth, derived fromnecrotic cells, mainly from themitochon-
dria. These are called “damage-associated molecular pat-
terns” (DAMP). It was a very important recognition that after
cellular injury similar proteins will be released during bacte-
rial infection, because the genetic background of the bacteria
and the mitochondria is very similar [20].This highlights the
fact that the Bone-concept inevitablymixed patients who suf-
fered insults due to PAMP, DAMP, or the mixture of the two.
Activation of neutrophils, macrophages, and monocytes
by costimulatory molecules at the site of infection will turn
the local adaptive immune system on and give “permission”
to the adaptive system to respond to an infectious insult. The
aim of the innate response is the eradication of the DAMP
and PAMP, which is followed by the adaptive response with
the resolution of the immunological process. The adaptive
immune response is based on maturation and proliferation,
both influenced by the “cytokine signature” of the innate
response. In other words, every host has its own “cytokine
signature” for a certain insult. Under normal circumstances
these processes are well regulated maintaining an even
balance between counteracting forces, hence keeping the
inflammatory response localized.
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Figure 1: The “sepsis-triangles”: pathomechanism and treatment. SIRS: systemic inflammatory response syndrome, I-R: ischemia-
reperfusion, DO2: oxygen delivery, VO2: oxygen consumption, PAMP: pathogen-associated molecular patterns, DAMP: damage-associated
molecular patterns, EC: extra corporeal, and IPPV: intermittent positive pressure ventilation.
However, in the case of an unbalanced (proinflammatory
and anti-inflammatory), dysregulated (maturation and pro-
liferation) response, the localized process goes out of control
and becomes systemic, in otherwords the disease of thewhole
body; hence, it gives way for impairing the function of distant
vital organs. This makes the clinical manifestation of critical
illness so similar regardless of the insult. To give an example,
the same gravity of acute respiratory distress syndrome
(ARDS), shock, or deterioration inmental function can occur
in pancreatitis, just aswell as aftermajor surgery, or due to any
type of infection (Figure 2). The adaptive immune system as
the third level of defense is based on itsmemories. It can adapt
and protect us against almost any invader.
In brief the “cytokine signature” of neutrophils and
macrophages will give signals to the T and B lymphocytes
via the dendritic cells, which after proliferation bymaturation
will express different cell surface receptors in soluble or
membrane bound forms. The adaptive immune response is a
soluble matrix, which consists of the cascade-type activation
of cytokines, coagulation factors, the release of acute phase
proteins, stress hormones, and different chemokines and
hormokines, forming a complex network. The key factor of
immune resolution is the balance between proinflammatory
and anti-inflammatory forces, which ismainly determined by
the balance between the relationship of Th1, Th2, Th17, and
𝛾ΔT to each other, namely, the maturation, magnitude, and
the duration of their activity [19].
4.2. Systemic Inflammatory Response Syndrome (SIRS) and
Immunoparalysis. Based on the Bone-criteria, systemic
inflammatory response syndrome, invented on the Con-
sensus Conference in 1991 [4], initially meant the classical
“sepsis syndrome” criteria, without proven infection. The
SIRS-criteria have also been criticized for similar reasons as
the “sepsis syndrome” definition, but nevertheless this “SIRS-
concept” assumed that systemic inflammatory response can
occur for an insult without infection.
In the past SIRS was mainly thought to be related
to the imbalance between the proinflammatory and anti-
inflammatory responses. However, it is more complex. In the
context of the innate and adaptive immune responses both
proinflammatory and anti-inflammatory processes take place
in a parallel fashion. When the proinflammatory and anti-
inflammatory forces swing into action, the proinflammatory
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forces overwhelm the anti-inflammatory process at the begin-
ning. In general we can say that there is a short delay of
the anti-inflammatory response as compared to the proin-
flammatory. This proinflammatory “dominance” lasts for 2
to 4 days, but an oversized response, which means that
the localized insult becomes systemic, will lead to different
degree of tissue damage, shock, and eventually organ failure.
During the course of disease the adaptive response is initiated
by Th1 reaction. In the next phase, the proinflammatory
process slowly “turns itself off,” while the adaptive response
will switch to a Th2 response. In other words, this later
phase helps to survive the proinflammatory process after
the eradication of the insult with “restitutio ad integrum”
[21]. However, a dysregulated, systemic form of the adaptive
response could later induce immunoparalysis, jeopardizing
the body’s defense, hence leaving it prone to further, even
opportunistic infections. There are many unanswered ques-
tions in this process, but discussing these issues in details goes
well beyond the scope of this paper [22].
4.3. The Altered Immune Response and Leukocyte Reprogram-
ming. In the later phase, in septic patients and in patients
with severe noninfectious SIRS (such as burns, trauma,major
surgery, hemorrhage, or ischemia-reperfusion after cardiac
arrest), the anti-inflammatory process may overwhelm the
proinflammatory forces. This is often referred to as “anergy,”
“endotoxin intolerance,” “immunoparalysis,” or “immun-
odepression,” but these are very general and simplified
descriptions of what is really happening. The term cellular
reprogramming may be more accurate indicating the cellular
changes during this process. In brief, cellular reprogramming
means two contradictory parallel cellular processes: cells
derived from hematopoietic compartments, such as bone
marrow, spleen, lymph nodes, and blood, become hypore-
active. In contrast, cells derived from other tissues and solid
organs (like liver, kidney, lung, brain, or gastrointestinal tract)
can often be hyperreactive causing hyperinflammation in
the particular organs, especially in the infected organ. The
inhibition of some signaling pathways parallel with others,
which are maintained or enhanced, results in large variety of
immune response. Immunosuppression itself does not cause
harm but leaves the patient prone to infection. Unfortunately,
tests able to measure the degree of immunosuppression are
not available all around the clock; hence, the clinician has
nothing else to rely on at the bedside than the etiology,
clinical picture, and biomarkers in order to detect the onset
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of a potentially devastating new infection as soon as possible
[21, 22].
5. Diagnostic Challenges
One of the most commonmisconceptions in sepsis diagnosis
is that we have been searching for specific “marker(s) of
sepsis.” However, there is not and there will never be one
single marker which is able to diagnose sepsis, mainly due
to the very colorful manifestation of sepsis and due to the
heterogeneity of patients.
Recognizing the septic patient has two main elements.
On the one hand, we have to evaluate vital organ function
and the degree of organ dysfunction via objective signs,
such as hypotension, hypoperfusion, altered mental status,
acid-base imbalance, hypoxemia, lactate levels, renal and
liver dysfunction, and thrombocytopenia. Based on these
findings we should start supportive therapy without any
further delay, and if there is any suspicion of the possibility
of an infection, empirical antibiotic therapy should also be
started immediately (Figure 1) [16].
In the meantime we have to diagnose the etiology of
critical illness. In other words we have to decide whether
critical illness is due to infection or not. Because if it is due to
infection antibiotics should be started as soon as possible, but
if it is not related to a bacterial infection, antibiotics are not
just a waste of time and money, but they may also do harm in
short and long term. Unfortunately, diagnosing infection in
critically ill patients is not easy.
5.1. Conventional Markers of Infection. Clinical signs are
the most important in recognizing critical illness, but
they cannot prove infection on their own. Conventional
(fever/hypothermia, leukocytosis/leukopenia, tachypnoe,
tachycardia, and hypotension) indicators, also listed in the
classical “sepsis-syndrome” criteria, are very nonspecific,
in fact poor indicators of infection. For microbiological
proof of infection, although very important, unfortunately
results become available 24–48 hours at the earliest after
sending the specimen to the laboratory. According to our
current concept, it is of utmost importance to start adequate
antibiotic therapy as soon as possible, but at least within
an hour after the onset of infection caused hypotension;
otherwise chances for survival are reducing by the hour [23].
New molecular biology techniques are now available
to define the presence of bacterial or fungal DNA within
the bloodstream of patients [24, 25]. Highly sophisticated
molecular biology based tests such as polymerase chain
reaction (PCR), matrix assisted laser desorption/ionization
(Maldi/Tof), and peptide nucleic acid fluorescence in situ
hybridization (PNAFISH) based pathogen detection can the-
oretically shorten the recognition of the underlying pathogen
to about 8 hours [26]. However, these cannot differentiate
between colonization and clinically significant infection.
Therefore, we need laboratory tests, which are sensitive and
specific enough to show the onset andmagnitude of bacterial
invasion caused inflammatory response as soon as possible
and may also be able to follow the progress of the disease
within hours. These biologically active substances are called
biomarkers.
5.2. The Role of Biomarkers at the Bedside. There have been
several biomarkers developed so far [1], but neither is suitable
for all purposes. Every marker has its own merit and limita-
tions. They inevitably can support decision making but they
will never be able to differentiate “sepsis” from “SIRS” with a
100% sensitivity and specificity, mainly due to the problems
we discussed earlier in details regarding the problems of
defining sepsis, and also due to the complex, overlapping
pathomechanism of PAMP and DAMP. Nevertheless, there
is still an ongoing search for better, new markers of inflam-
matory response and infection, with promising preliminary
results [40].
There are almost 200 so-called sepsis markers; therefore,
discussing the features of those cannot be integrated into
the current review. We will mainly focus on the two most
commonly usedmarkers: procalcitonin (PCT) andC-reactive
protein (CRP). However, briefly mentioning the main fea-
tures of a few other newmarkers already applied in daily prac-
tice, such as soluble CD14 subtype (presepsin) and soluble
urokinase-type plasminogen activator receptor (suPAR),may
be worthwhile. Higher presepsin concentrations in septic
patients were associated with ICU mortality in a recent large
multicenter trial [41]. It was also suggested that changes in
plasma concentrations may reflect the appropriateness of
antibiotic therapy, but this have to be confirmed by future
studies [41]. Regarding the suPARmolecule it has been shown
to be a very good indicator of severity of the acute disease and
shows good correlation with the degree of organ dysfunction
in the critically ill but cannot be regarded as a “sepsis marker”
due to its low specificity [42].
Any condition inducingDAMP [43] or PAMP could shed
the endothelial glycocalyx layer. It has been confirmed in
several experimental studies in different septic models that
damage of the endothelial glycocalyx layer is reflected in
elevated serum syndecan-1 and syndecan-4 levels [44–47],
which may be potentially a very interesting marker in the
future, but again, it may be nonspecific for bacterial infection
only.
Finally, neutrophil-lymphocyte count ratio is a cheap,
fast, and easily available tool to diagnose bacteremia and
was found to improve bloodstream infection diagnostics in
a recent study on the emergency ward [48]. This simple test
may also have a potential in the future.
Nevertheless, the two most commonly used markers
in infection/sepsis diagnostics and for guiding therapeutic
interventions are PCTandCRP [49].Despite their popularity,
there are still many pros and cons without clear answers
regarding their usefulness and interpretation in guiding
patient management.
Procalcitonin is detectable in the serum within a few (4–
6) hours after the onset of bacterial infection. During the
“normal” course of an infection it reaches its peak within
24 hours and then starts its decline in the case of adequate
treatment with levels reducing by roughly 50% daily accord-
ing to its half-life [27]. In contrast, CRP moves “slowly,”
and under similar circumstances it reaches its maximum
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Table 1: Comparison of CRP versus PCT (advantages and disadvantages).
CRP PCT
Differentiating bacterial infection from SIRS − [27] Specific for bacteria [28, 29]
Response to infection Slower (days) [27] 2–6 hours [30]
Peak response after infection 2-3 days [27] 12–48 hours [27]
Half-life Several days [27] 20–35 hours [31]
Plasma kinetic Slow [27] Rapid [27]
Price + ++++
Correlating disease severity and progression Slightly [27] +++ [32]
Correlating effective therapy + +++ [33, 34]
Prognostic factor for mortality Weak or nonexistent [27] Good predictor [31, 32]
Differentiating G+ from G− − [35] ++ [35]
Response to other factors
Virus, autoimmune diseases,
local infections, surgery, trauma
[27]
Surgery, trauma, burn,
cardiogenic shock, liver cirrhosis
[36–38]
Fungal infection same as bacterial [35] Slightly elevated [35]
Immunosuppression Formation can be changed [27] The induction is reduced [27]
Biological effect Opsonin for phagocytosis [27] Chemokine [27]
Sensitivity/specificity Sensitive but nonspecific [27] Sensitive and specific [27, 39]
General use Outpatient care [27] In intensive care [27]
value usually within 48 hours. However, levels are generally
elevated in most ICU patients, making interpretation of CRP
very difficult [50]. The other major problem with CRP on
the ICU is that it is lagging way behind the actual events of
the inflammatory process. The most important differences
between the two markers are summarized in Table 1.
Procalcitonin differentiates bacterial infections from sys-
temic inflammatory response of other etiologies with higher
sensitivity and specificity compared to CRP [39]. There is
considerable evidence that PCT supported decision making
during antibiotic treatment has several beneficial effects. It
considerably reduced antibiotic use in lower respiratory tract
infections without compromising survival [51], and it may
also shorten the duration of antibiotic treatment on the ICU
[52].
Although in the coming paragraphs we will mainly refer
to studies investigating PCT, the concept how to interpret
these data is potentially applicable for any inflammatory
marker and should be taken into account when evaluating
biomarker levels at the bedside.
6. Interpreting PCT
6.1. Sepsis Is Different in Surgical and Medical Patients.
Although sepsis is often referred to as a “definitive disease”
(see above), in a clinical trial published more than 10 years
ago, PCT levels were found to be several folds higher in
surgical as compared to medical patients in septic shock
despite the similar clinical manifestation and severity of
the clinical picture [53]. This indicates different degree of
inflammatory response depending on etiology. Indeed, there
is increasing evidence that, in the case of massive cell injury,
such as in severe trauma [54], after major surgery [55], and
any ischemia-reperfusion type injury including cardiogenic
shock [37], due to the mechanism of DAMP [56], unspecific
elevations of PCT levels can typically be seen even in the
absence of a bacterial infection [57, 58]. Theoretically, in
surgical patients with sepsis DAMP and PAMP take place
at the same time leading to an overwhelming inflammatory
response, whilst in medical patients it is primarily the activa-
tion of the PAMP, resulting in a less extensive inflammatory
response, hence lower biomarker levels [53]. In the study by
Clec’h et al., the median PCT value in SIRS in medical versus
surgical patients was 0.3 (0.1–1.0) versus 5.7 (2.7–8.3), and
in septic shock: 8.4 (3.6–76.0) versus 34.0 (7.1–76.0) ng/ml,
respectively.
Another very important addition to these findings was
provided by a study by Charles et al., in which they found
different degree of inflammatory response in patients with
the first as compared to those with the second septic insult
[59]. They investigated patients with primary and secondary
blood stream infections and found that the same gravity of
infection was accompanied by a severalfold lower maximum
PCT level in patients during the second event of infection
as compared to those with a primary event. The receiver
operating characteristic curve of serumPCT for the diagnosis
of blood stream infection in critically ill patientswith primary
sepsis with a cutoff value of 55.6 ng/mL was 0.934, 95% CI:
0.881–0.970, and in patients with secondary sepsis with a
PCT cutoff 6.4 ng/mL it was 0.805, 95% CI: 0.699–0.879.This
observation is in accord with what we have already discussed
about immunoparalysis and cellular reprogramming in the
previous paragraphs put into context with PCT in Figure 3.
This shows that lower levels of PCT should be taken seriously
in the case of a leter (secon or third) onset of infection and this
concept has been further supported by several recent reports
[60, 61].
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These studies clearly show that a given PCT value should
be interpreted differently based on etiology and the time
course of the critically ill condition. It is obvious that “one
size [of biomarker] does not fit all”; hence, careful evaluation
of the given clinical scenario cannot be neglected when
interpreting a given laboratory result. Before we discuss the
importance of kinetics of biomarkers, let us put the results of
recently published clinical trials into this context first.
Recent large clinical trials tested the effectiveness of PCT-
guided antibiotic strategies applying the “one size does fit
all”; in other words predetermined absolute values (e.g.,
>1 ng/mL) as a concept and the results were either nonsignif-
icant or patients required mechanical ventilation longer and
the prolonged use of antibiotics in the PCT-arm [62, 63].
However, the percentage of surgical patients was around 40%
in both studies, and the PCT value indicating the need for an
intervention was chosen to be ≥1 ng/mL. Based on the results
of previous studies investigating PCT levels in surgical and
medical patients, as we discussed before, this 1 ng/mL cutoff
value for intervention is a very low PCT value in a specific,
mainly high risk surgical population. Indeed, in the study
by Layios et al., in patients with a PCT ≥1 ng/mL antibiotics
were withheld only in 11%. Although data were not provided
for this subgroup of surgical patients, one may assume
that these patients received antibiotics unnecessarily in large
proportion. The same may hold true for the PASS study
that unnecessary antibiotic use, and antibiotic escalation, was
inevitable in the PCT-group due to the generally low “alert-
PCT” levels (≥1 ng/mL) in the study protocol [63]. However,
if a biomarker’s half-life is short enough, taking kinetics into
account, instead or in addition to their absolute values, may
provide several theoretical benefits.
6.2. Kinetics over Absolute Values. Although the absolute val-
ues of PCT show substantial differences in different etiologies
and the course of the disease, but the kinetics may be similar
andmore useful. Tsangaris et al. studied 50 patients whowere
in the ICU for more than 10 days, free of infection and who
presented with a new onset of fever. Procalcitonin showed a
minimumof 2-fold increase in 27 patients from the day before
to the day of fever onset, and in these patients infection was
eventually proven. On the contrary, infection was not proven
in 23 patients in whom PCT remained persistently low and
unchanged as compared to previous days. Their conclusion
was that a twofold increase of PCT between fever onset
and the previous day was associated with proven infection.
Furthermore, a normal PCT value on the third day after the
fever onset was associated with better survival. It is important
to note that the observed maximum PCT values in patients
with proven infection remained relatively low (<1.5 ng/mL),
but it was not the absolute value but the severalfold increase,
which indicated acute onset of infection [64].
This takes us to the importance of PCT kinetics. In most
studies PCT kinetics were mainly tested to predict severity
and outcome rather than to guide therapy [32, 65]. In a
recent pilot study in patients treated on the ICU, we found
significant differences in the change of PCT from the day
before (Day
−1
) to the day when new infection was suspected
according to the clinical picture (Day
0
). OnDay
−1
PCT levels
were similar in patients in whom infection was eventually
proven as compared to patients in whom we could not
prove infection. Although on Day
0
absolute values of PCT
levels were elevated in both groups, levels were significantly
higher in patients in whom infection was later proven. Most
importantly, while there was no significant change in the
levels of PCT fromDay
−1
to Day
0
in the noninfectious group,
the rate of increase was significant in the infection group [34].
It has also been shown that PCT kinetics (>80% drop from
its maximum value) can be very useful in stopping antibiotic
therapy early, hence reducing antibiotic consumption and
length of treatment significantly, which is also recommended
in the recent Surviving Sepsis Guideline [6, 52]. These results
8 Journal of Immunology Research
suggest that therapy based on PCT kinetics may be superior
as compared to predefined absolute values, a hypothesis to be
tested in the future.
6.3. Fungal and Viral Infections. Recent studies show that
fungal infections have an increasing tendency in critically ill
patients [66, 67]. Candida spp. are the third or fourth most
commonly isolated microorganism in the bloodstream of
ICU patients and its associated mortality is reported to be as
high as 40–60% [67, 68]. Candidemia or invasive candidiasis
is defined by positive blood cultures and presence of clinical
signs of systemic infection. Fungal infections are difficult to
diagnose from blood cultures because it takes a considerable
amount of time to grow these organisms and it often remains
negative [69, 70]. Unfortunately, clinical features are very
nonspecific to separate bacteria-related sepsis from Candida
sepsis. A number of clinical trials have proposed the potential
diagnostic value of PCT in this context. Martini et al.
investigated PCT levels for the diagnosis of candidemia or
bacteremia in septic patients.They have found that a low PCT
value (0.71 [0.5–1.1] ng/mL 𝑝 = 0.001) in a critically ill septic
patient is more likely to be related to candidemia than to
bacteremia [71]. Another trial by Cortegiani et al. reported
that PCT could be a useful diagnostic tool to separate
Candida spp. blood stream infection (0.99 ng/mL, 0.86–1.34)
from blood stream infection caused by bacteria (16.7 ng/mL,
7.65–50.2) or in mixed infections (4.76 ng/mL, 2.98–6.08).
Therewas no difference in PCT levels to exclude the detection
of Candida spp., by blood culture (alive Candida) and real-
time PCR (killed Candida) in septic patients. In this study
significantly lower values of PCT were observed in [72].
Markova´ et al. determined the role of PCT testing
in patients with high risk for invasive fungal infection.
They included immunocompromised hematological patients
undergoing chemotherapy or allogeneic hematopoietic stem
cell transplantation and had bacterial or fungal infectious
complications. C-reactive protein and PCT were prospec-
tively assessed from the day following fever onset for four
consecutive days. They found increased CRP combined with
mildly or not elevated PCT in immunocompromised patients
probably due to fungal infection. Therefore, the complemen-
tary use of these biomarkers may help the diagnostic method
[35].
A recent systemic review and meta-analysis summarized
current evidence on the role of PCT in differentiating fungal
infections from other infectious diseases. They identified 8
eligible studies and summarized 474 episodes of suspected
fungal infections. The most frequently isolated causative
organisms were Candida albicans, Candida parapsilosis, Can-
dida glabrata,Candida tropicalis,Aspergillus spp., and Penicil-
lium zygomycota. They found that PCT has a good diagnostic
power to separate invasive fungal and bacterial infection from
noninfectious disease conditions [73].
Another clinical trial investigated the differences between
Gram-negative (G−), Gram-positive (G+), and fungal blood-
stream infections. They observed significantly higher PCT
levels in patients with G− as compared to G+ infections and
even lower levels in fungemia [74].
Regarding viral infections, most of the published results
agree that PCT can differentiate between viral and bacterial
infections, as levels will remain low in the latter case [75–
77]. However, it is important to acknowledge that any con-
dition, including sever viral infection, nonbacterial systemic
inflammatory condition such as sterile acute pancreatitis or
any ischemia-reperfusion injury, which is accompanied with
significant hypotension/hypoperfusion of the tissues, can
cause a DAMP-induced PCT increase, whichmay complicate
differential diagnosis [56, 78, 79].
7. Treatment: What the Future Holds?
7.1. Extracorporeal Removal of Mediators and Toxins. Extra-
corporeal clearance of the plasma, via hemofiltration and
plasma pheresis, has received major interest over the last
decades in sepsis research. As the results were contradictory,
nowadays the focus of interest has turned towards new
alternatives, such as the targeted removal of toxins and
mediators via specific adsorption.
7.1.1. Polymyxin-B. Polymyxin-B (PMX-B) is a cyclic cationic
polypeptide antibiotic originated from Bacillus polymyxa.
This antibiotic has the facility to bind and neutralize endo-
toxins [80]. Studies have shown that PMX-B blunts the TNF-
𝛼 response to endotoxin [81], which is due to the high binding
affinity of PMX–B for the LPS molecules. Unfortunately,
PMX-B infusion causes nephrotoxicity and neurotoxicity
in humans [82]. However, when polymyxin B is linked
covalently to a polystyrene-derived fiber in a hemoperfusion
cartridge, it can be used to remove circulating endotoxins
without exerting its undesired effects systematically. The
surface area of the column is extremely large, so it can clear up
a large amount of circulating endotoxins in a relatively short
period of time [83]. Another potentially beneficial effect of
PMX-B hemoperfusion is the removal of certain inflamma-
tory cells [84]. This device has been used and tested in many
patients with a very low incidence of adverse events (<1%),
such as thrombocytopenia, allergic reactions, and transient
hypotension [82]. As PMX-B hemofiltration has been avail-
able for several years, it cannot be regarded as a “new” treat-
ment alternative per se; nevertheless, it is far from routine use
in the everyday practice; hence, future studies are warranted.
7.1.2. CytoSorb. CytoSorb is a hemadsorption device. It
removes both proinflammatory and anti-inflammatory
cytokines. The cartridge contains biocompatible, greatly
porous polymer beads capable of absorbing molecules in the
∼10–50 kDa range [85–87].
Cytokine overproduction is a common feature in many
life-threatening conditions in addition to sepsis, such as
trauma, major surgery in high risk patients, viral infections,
acute respiratory distress syndrome (ARDS), serious burn
injury, and acute pancreatitis, liver failure just to name a
few. Several case reports have been published about the
use of CytoSorb treatment over the last couple of years.
These include 𝛽-hemolytic streptococcus-induced necrotiz-
ing fasciitis [88], septic shock with multiorgan dysfunction
[89], and rhabdomyolysis [90]. Elevated cytokine levels
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have been reported during donor conditioning for organ
transplantation, which were associated with dysfunction of
donor organs before and after transplantation [91, 92]. In a
recent clinical trial it was found that, in addition to conven-
tional treatment, attenuating the inflammatory response by
cytokine absorption, graft survival can be prolonged [91].
7.2. Anti-PD-1 Immunotherapy in Sepsis and Tumor Diseases.
The late phase of sepsis and the late phase of cancer by-
and-large share similar immune suppression mechanism.
One of the similarities is based on the presence of negative
costimulatory molecules, such as PD-1 (programmed cell
death-1). Its expression is induced primarily on T cells’
CD4 and CD8 surface proteins, the signaling via which
PD-1 inhibits T cell proliferation, cytokine production, and
cytotoxic ability. Persistent antigen exposure (DAMP-PAMP)
causes increased levels of PD-1 consequently T-cell depletion
[93, 94].Theoretically, blocking the PD-1 receptor or its ligand
by antibodies could reverse T cell dysfunction and inhibit
the pathogen or tumor cells initiated immunosuppression
[94]. Inhibition of the PD-1 pathway in animal models
resulted in clinically significant survival benefit in bacterial
and fungal sepsis [95, 96]. In a recent clinical trial, patients
with lung cancer, melanoma, and small-cell renal cancer
patients responded to anti-PD-1 antibody treatment in 20 to
25% [97]. Based on the similar immune-pathomechanism of
cancer and sepsis, testing the effect of anti-PD-1 or anti-PD-L1
in the future certainly makes sense. Furthermore, since septic
patients do not require long-term anti-PD-1 or anti-PD-L1
therapy the potential adverse effects of certain autoimmune
reactions or other serious complications should be very rare.
Therefore, future studies are warranted to confirm safety
and efficacy issues of anti-PD-1, anti-PD-1L treatment in
immunoparalysed septic patients [98]; furthermore, evaluat-
ing PD-1 or PD-L1 expression in immune cellsmay be a useful
biomarker for immunomodulatory therapy.
7.3. Stem Cells and Genetic Treatment. Bone marrow-derived
multipotent mesenchymal stem cells (MSCs) are already
in the clinical use in multiple clinical disorders including
myocardial infarction [99], diabetes [100], hematological
malignancies [101], hepatic [102], and renal failure [103].
Recent animal experiments suggested that bone marrow-
derived MSCs may also have a potential role in the treatment
of acute renal failure, ARDS, and sepsis [104–106].
In several recent animal models in mice, investigating
drug- and ischemia-reperfusion-induced acute kidney injury,
MCSs therapy was found to enhance recovery and prolong
survival [104, 107, 108]. In other animal models circulating
MSCs were able to help to regenerate new renal tubular cells
in acute kidney injury [109, 110].
MSCs can also be potentially used in ARDS by atten-
uating proinflammatory response by regulating both the
innate and adaptive immune systems and modulation of
macrophages [111]. They can influence activated CD4 and
CD8 T cells via the inhibition of the inflammatory cytokine
production and stimulate the regulatory T cells. MSCs
can directly affect sepsis, one of the most common causes
of ARDS, by enhancing macrophage phagocytosis and
increasing antimicrobial peptide secretion, thereby increas-
ing bacterial clearance [106, 111]. Another animal experiment
showed that MSCs can also help to repair the injured
lung following ventilation-induced lung injury [112]. There
is increasing evidence about the potential mechanisms via
which MSCs act in the injured lung [113]. There is one ongo-
ingmulticenter clinical trial on the effects of allogeneicMSCs
therapy in patients with moderate to severe ARDS, in which
patient recruitment has already started [ClinicalTrials.gov,
NCT01775774].
As patients respond differently for seemingly same infec-
tious insults, genetic variants are likely to explain the differen-
tial susceptibility in the risk of severe sepsis. It is obvious that
host genetics can influence sepsis outcomes but no specific
loci have yet been confirmed.This year, the first genome-wide
study reported significant correlation between certain single
nucleotide polymorphisms and 28-day mortality in intensive
care patients with sepsis, severe sepsis, or septic shock [114].
After the exact clarification of some responsible loci and its
role in the background, mechanism, and course of sepsis,
genetic manipulation may be another potential therapeutic
approach of sepsis therapy in the future.
8. Conclusion
Understanding the underlying pathology in sepsis and criti-
cal illness in general is inevitable in order to evaluate clinical
signs and biomarkers in the right context at the bedside.
In-depth analysis of recent research shed light on several
important issues including the immunological background of
host response for different insults summarized in the DAMP
andPAMP concept, which also explains why biomarker levels
should be interpreted differently based on etiology and why
their kinetics may carry more appropriate information than
the absolute values. Furthermore, this understanding may
lead us to a completely different strategy in treatment where
the major role will be played by adsorption techniques and
cellular reprograming.
However, this knowledge also revealed that in the com-
plex condition of sepsis nothing will ever replace the well
trained, experienced, thinking physician, who takes all of
the available information into consideration at the bedside
and then makes a decision. Finally, even if this decision
will be proved to be wrong retrospectively, it should not be
interpreted as a failure, but rather as an important source
of our experience. This experience, which contradicted our
expectations and disappointed us at the time, leads to the
design of several research projects and more importantly
it already helped us to understand more about sepsis and
changed the waywe thought about it 30 years ago, completely.
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